Skip to main content

Conference Highlights ASH

Conference Highlights ASH
Chemoimmunotherapy with Fludarabine, Cyclophosphamide, and Rituximab versus Bendamustine and Rituximab in Previously Untreated and Physically Fit Patients with Advanced Chronic Lymphocytic Leukemia
Read More
Conference Highlights ASH
Safety and Efficacy of Obinutuzumab (GA101) with Fludarabine Cyclophosphamide or Bendamustine in the Initial Therapy of Patients with Chronic Lymphocytic Leukemia: Results from the Phase 1b GALTON Trial
Read More
Conference Highlights ASH
Chronic Lymphocytic Leukemia: A New Treatment Era is Born
Read More
Conference Highlights ASH
Head-To-Head Comparison of Obinutuzumab Plus Chlorambucil versus Rituximab Plus Chlorambucil in Patients with Chronic Lymphocytic Leukemia and Coexisting Medical Conditions: Final Stage 2 Results of the CLL11 Trial
Read More
Conference Highlights ASH
Siltuximab: Monoclonal Antibody Relieves Symptoms of Castleman’s Disease
Read More
Conference Highlights ASH
More Transplants Made Possible Through Haploidentical Donors
Caroline Helwick
Read More
Conference Highlights ASH
Hospital Readmission After Stem-Cell Transplant Decreases Survival
Wayne Kuznar
Read More
Conference Highlights ASH
JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis
Wayne Kuznar
Read More
Conference Highlights ASH
Ready-Made Platelets? A Boon for Patients If It Works
Neil Canavan, Neil Canavan
Read More
Conference Highlights ASH
High Morbidity Burden Borne Years Later by Survivors of Transplant
Caroline Helwick, Caroline Helwick
Read More
Page 3 of 4
Results 21 - 30 of 35